Emcure PharmaQ2 FY25

Emcure Pharma Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,339.4P/E: 39.9Market Cap: ₹44.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
- Emcure expects overall revenue growth of 20%+ for FY25, with better momentum in H2 compared to H1. - Organic business growth is around 12%, supported by volume growth ahead of Indian pharmaceutical market (IPM) average. - Volume growth was about 3-4%, pricing up 2-3%, and new product introductions contributing 2-3%. - Domestic business aims to grow faster than industry high single-digit growth. - International business, especially emerging markets, expected to grow in low double digits organically. - European business is targeted to achieve double-digit growth from FY26 onward. - ARV (anti-retroviral) segment is expected to show strong recovery and growth visibility for FY25. - Field force expansion is targeted to support growth in tier 2 and tier 3 geographies for India business. - Acquisition-led growth will complement organic growth in the next 2-3 years. (Approx. 140 words)

See what Emcure Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or future new fundraising through debt or equity in the provided transcript from the Emcure Pharmaceuticals Q2 FY25 earnings call.
  • The company highlighted a reduction in net debt from INR 1,558 crores at the start of the fiscal year to INR 705 crores at quarter-end, indicating deleveraging.
  • Interest cost is expected to reduce further by around INR 25 crores in the second half due to debt reduction.
  • No direct references were made about plans for new equity issuance or additional borrowings.
  • The management emphasized focusing on organic growth, operational leverage, and selective acquisitions rather than indicating plans for fresh fundraising via debt or equity.

See what Emcure Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes
- Emcure has operationalized four new plants recently, contributing to increased depreciation expenses, indicating recent capital investments in manufacturing capacity. - The company is focusing on building the Derma business through a new 100% owned subsidiary, Emcutix, which implies strategic investment in new therapeutic areas. - Expansion in salesforce with a vertical split to support strong brands and new product launches also suggests investment in commercial capabilities. - Emcure continues to look actively for acquisition opportunities domestically and internationally, which will involve strategic capital deployment. - No specific future capex amounts or timelines detailed, but focus on operating leverage and productivity improvements indicates ongoing and future investments aimed at margin enhancement. Overall, Emcure is investing strategically in capacity expansion, new therapy segments, and inorganic growth avenues without specifying exact capex plans.

Track Emcure Pharma — get its next earnings analysis in your feed

How does Emcure Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisEmcure Pharma
Rev 2Mar 2

How does Emcure Pharma rank in Pharmaceuticals & Biotechnology?

Compare Emcure Pharma against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →